Genmab — Oktober 2015
-
Godt nok var det en stærk dag i går - men sikke vi hænger i bremsen i dag
-
Går lidt fremad igen.
-
det er et fænomenalt kursniveau, vi ser - specielt ifht biotek i US. Nu skal der nyheder på bordet
-
Haha! Så kan ham Martin Skræklig fra Turing lære det - http://www.bt.dk/udland/satte-prisen-paa-aids-medicin-op-fra-90-til-5000-kroner-nu-har-usas-mest-hadede-man
-
GILD tjente $13 bn i de første tre kvartaler. De har $25 bn i cash. Alt nok til en pænt bud på Genmab... http://finance.yahoo.com/news/gilead-sciences-announces-third-quarter-200000138.html
-
God morgen.

-
Det ser sådan ud.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind